Associate Professor of Biology
Member, Whitaker Cardiovascular Institute
PhD, Baylor College of Medicine, 1997
Areas of interest: cardiac development and disease, muscle regeneration, muscular dystrophy, mouse developmental biology, gene regulation
One of our areas of study focuses on dissecting the in vivo role of the myocyte enhancer factor-2 (MEF2) family of transcription factors in muscle development. The four mammalian mef2 genes—mef2a, mef2b, mef2c, and mef2d—are co-expressed in cardiac and skeletal muscle. Loss-of-function studies in mice have revealed important yet distinct functions for the vertebrate mef2 genes in the heart. Inactivation of the mef2c gene results in defective cardiac morphogenesis in developing embryos. In contrast, inactivation of the mef2a and mef2d genes results in perinatal cardiomyopathy and altered stress-dependent cardiac remodeling, respectively. Exploring the downstream cellular pathways controlled by the various mef2 genes will help us understand the genetic pathways in muscle development and disease.
Another area of investigation relates to the role of scaffolding proteins, i.e. proteins that bind signaling enzymes, in muscular dystrophy. Muscular dystrophy is a severe muscle degenerative disease and one form of this disease is the result of a deficiency in dystrophin. Significantly, we have identified a muscle-specific scaffolding protein, myospryn, that interacts with protein kinase A (PKA) and dystrophin. Because the signaling pathways involved in muscular dystrophy are still poorly understood, we are looking into the potential role for myospryn in this process.
- BI 553 Molecular Biology 2
- Snyder CM, Rice AL, Estrella NL, Held A, Kandarian SC, Naya FJ (2013). MEF2A regulates the Gtl2-Dio3 microRNA mega-cluster to modulate Wnt signaling in skeletal muscle regeneration. Development. 140(1):31-42.
- Ewen EP, Snyder CM, Wilson M, Desjardins D, Naya FJ (2011). The Mef2A transcription factor coordinately regulates a costamere gene program in cardiac muscle.J Biol Chem. 2011 Aug 26;286(34):29644-53.
- Kielbasa OM, Reynolds JG, Wu CL, Snyder CM, Cho MY, Weiler H, Kandarian S, Naya
FJ (2011). Myospryn is a calcineurin-interacting protein that negatively modulatesslow-fiber-type transformation and skeletal muscle regeneration. FASEB J. 2011 Jul;25(7):2276-86.
- McCalmon SA, Desjardins D, Ahmad S, Davidoff K, Snyder CM, Sato K, Ohashi K, Kielbasa O, Mathew M, Ewen EP, Gavras H, Walsh K, Naya FJ. (2010). Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ Res. 106(5):952-60.
- Reynolds JG, McCalmon SA, Donaghey JA, Naya FJ. (2008). Deregulated PKA signaling and myospryn expression in muscular dystrophy. J Biol Chem, 283(13):8070-4.
- Reynolds JG, McCalmon SA, Tomczyk T, Naya FJ. (2007). Identification and mapping of protein kinase A binding sites in the costameric protein myospryn. Biochim Biophys Acta. 1773(6), 891-902.
- Huang HT, Brand OM, Mathew M, Ignatiou C, Ewen EP, McCalmon SA, Naya FJ. (2006). Myomaxin is a novel transcriptional target of MEF2A that encodes a Xin-related alpha-actinin-interacting protein. J Biol Chem; 281(51), 39370-9.
- Durham JT, Brand OM, Arnold M, Reynolds JG, Muthukumar L, Weiler H, Richardson JA, Naya FJ. (2006). Myospryn is a direct transcriptional target for MEF2A that encodes a striated muscle, alpha-actinin-interacting, costamere-localized protein. J Biol Chem. 281(10), 6841-9.